Novo Nordisk Ozempic approved in the EU for the treatment of type 2 diabetes

Novo Nordisk (CPH:NOVO-B) announced that the European Commission (EC) has granted marketing authorisation for Ozempic^® (semaglutide) for the treatment of adults with type 2 diabetes. Ozempic^® is a new once-weekly analogue of human glucagon-like peptide-1 (GLP-1) indicated as monotherapy when metformin is considered inappropriate due to intolerance or is contraindicated, and as an addition to other medicinal products for the treatment of diabetes.

As quoted in the press release:

“We are very excited about the approval of Ozempic^® in the EU, as we believe it has the potential to set a new standard for the treatment of type 2 diabetes,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer. “Type 2 diabetes is a complex disease and the strong clinical profile of Ozempic^® provides a much needed treatment option for people looking for efficacious solutions to manage their disease.”

Click here to read the full press release.